|Bid||1.90 x 1300|
|Ask||7.99 x 800|
|Day's Range||6.77 - 7.30|
|52 Week Range||2.36 - 15.92|
|Beta (3Y Monthly)||1.17|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 5, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||16.33|
Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today provided clinical updates on XEN1101, a Kv7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders and XEN901, a potent, highly selective Nav1.6 sodium channel inhibitor being developed for the treatment of epilepsy. Xenon announced final results from its XEN1101 Phase 1 clinical trial and the related transcranial magnetic stimulation (TMS) studies, along with interim results from its XEN901 Phase 1 clinical trial, in posters at the American Epilepsy Society (AES) Annual Meeting held in New Orleans, LA.
BURNABY, British Columbia, Nov. 30, 2018 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will host a conference.
Warren Lammert founded Granite Point Capital, a long/short hedge fund with a focus on small-cap companies, in January 2004. The fund is headquartered in Boston, Massachusetts, and Mr. Lammert is its portfolio manager. Prior to launching his own fund, Warren Lammert honed his investment acumen for 14 years at Janus Capital Management LLC as a […]
Simon Pimstone has been the CEO of Xenon Pharmaceuticals Inc (NASDAQ:XENE) since 2003. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth Read More...
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
BURNABY, British Columbia, Nov. 07, 2018 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone,.
The Burnaby, British Columbia-based company said it had a loss of 63 cents per share. Losses, adjusted for non-recurring costs, were 33 cents per share. Xenon Pharmaceuticals shares have more than tripled ...
Robust, Novel Pipeline of Neurology Candidates Advancing in Clinical Development Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Nov. 06, 2018 -- Xenon.
BURNABY, British Columbia, Oct. 30, 2018 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its third.
A steady influx of foreign as well as domestic investments in U.S. healthcare has gone a long way in boosting gains for the space.
Xenon Pharmaceuticals Inc. (XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced the closing of its previously announced public offering of 4,500,000 common shares pursuant to its existing shelf registration statement at a public offering price of $14.00 per share. The gross proceeds to Xenon from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Xenon, were $63.0 million. Jefferies LLC and Stifel acted as joint book-running managers for the offering. Bloom Burton Securities Inc. acted as financial advisor to Xenon in connection with the transaction.
Xenon Pharmaceuticals Inc’s (NASDAQ:XENE): Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. With the latest financial year loss ofRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Stocks that hit 52-week highs Sept. 7.) Amgen, Inc. (NASDAQ: AMGN )/p BioSpecifics Technologies ...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 30) Acceleron Pharma Inc (NASDAQ: XLRN ) Avid Bioservices Inc (NASDAQ: ...
Biotech stocks saw a resurgence this week, as a post-earnings follow-up rally and company-specific news offered support. The iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB ) gained about 1.5 percent. ...
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of 8.16% and -100.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Burnaby, British Columbia-based company said it had a loss of 45 cents. Xenon Pharmaceuticals shares have more than tripled since the beginning of the year. In the final minutes ...